Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas

Area of Science:

• Oncology
• Immunotherapy
• Cancer Stem Cell Biology

Background:

• Unresectable metastatic bone and soft-tissue sarcomas (STS) are challenging to treat due to chemoresistant cancer stem-like cells (sCSCs) driving relapse and drug resistance.
• Current therapeutic strategies often fail to eradicate these sCSCs, leading to poor patient outcomes in advanced sarcoma cases.

Purpose of the Study:

• To investigate the preclinical efficacy of patient-derived cytokine-induced killer (CIK) cells against autologous bone and STS, specifically targeting putative sCSCs.
• To evaluate the in vitro and in vivo anti-tumor activity of CIK cells in sarcoma models.

Main Methods:

• Patient-derived CIK cells were expanded and tested against allogeneic and autologous sarcoma cells in vitro.
• Autologous sarcoma cells were engineered with a reporter vector to identify and track putative sCSCs.
• The anti-tumor effect of CIK cell infusion was assessed in an immunodeficient mouse model of autologous sarcoma.

Main Results:

• CIK cells demonstrated efficient killing of both allogeneic and autologous sarcoma cells in vitro.
• Intravenous administration of CIK cells resulted in delayed tumor growth in vivo.
• CIK cells infiltrated tumors and inhibited growth without causing an enrichment of sCSCs.

Conclusions:

• These findings provide preclinical proof-of-concept for CIK cells as a potent immunotherapy against sarcomas, including sCSCs.
• CIK cell therapy represents a promising novel approach for treating patients with untreatable metastatic bone and STS.
• Further clinical development of CIK cells is warranted for advanced and metastatic sarcoma treatment.